Do you want to read an article? Please log in or register.
Fingolimod alters the transcriptome profile of circulating CD4+ cells in multiple sclerosis
Multiple Sclerosis
Related content
Multiple Sclerosis
Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis
Cell.
Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R
doi: 10.1016/j.cell.2018.08.011.
SPECIAL REPORT
Multiple Sclerosis
Vaccination Readiness in Multiple Sclerosis
RECOMMENDED
Multiple Sclerosis
Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders
J Neurol.
Ellrichmann G, Bolz J, Peschke M, Duscha A, Hellwig K, Lee DH, Linker RA, Gold R, Haghikia A
doi: 10.1007/s00415-018-9092-4.
Multiple Sclerosis
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy in paediatric patients with multiple sclerosis: Results from the PARADIGMS study
Mult Scler.
Chitnis T, Banwell B, Krupp L, Arnold DL, Bar-Or A, Brück W, Giovannoni G, Greenberg B, Ghezzi A, Waubant E, Rostasy K, Deiva K, Huppke P, Wolinsky JS, Zhang Y, Azmon A, K-Laflamme A, Karan R, Gärtner J
doi: 10.1177/1352458520936934.
RECOMMENDED
EpilepsyMultiple Sclerosis
Trial of Fingolimod versus Interferon Beta-1a in Pediatric Multiple Sclerosis
N Engl J Med.
Chitnis T, Arnold DL, Banwell B, Brück W, Ghezzi A, Giovannoni G, Greenberg B, Krupp L, Rostásy K, Tardieu M, Waubant E, Wolinsky JS, Bar-Or A, Stites T, Chen Y, Putzki N, Merschhemke M, Gärtner J, PARADIGMS Study Group
doi: 10.1056/NEJMoa1800149.
Multiple Sclerosis
The real-world effectiveness and safety of fingolimod in relapsing-remitting multiple sclerosis patients: An observational study
PLoS One.
Izquierdo G, Damas F, Páramo MD, Ruiz-Peña JL, Navarro G
doi: 10.1371/
RECOMMENDED
Multiple Sclerosis
Advances in oral immunomodulating therapies in relapsing multiple sclerosis
★ 3
Recommended by
Prof. Dr Christian Kamm, Faculty Member
★ 2
Recommended by
Prof. Dr Claudio Gobbi, Faculty Member
Lancet Neurol.
Derfuss T, Mehling M, Papadopoulou A, Bar-Or A, Cohen JA, Kappos L
doi: 10.1016/S1474-4422(19)30391-6.
Multiple Sclerosis
Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis
JAMA Neurol.
Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.
doi: 10.1001/
Multiple Sclerosis
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
Eur J Neurol.
Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J
doi: 10.1111/ene.13936.